Company Profile

Company Name AntiCancer Technologies Inc.
English Name AntiCancer Technologies Inc. (Abbreviation: ACT)
Representative Director Teruyasu Nishino
Capital 65,500,000 JPY
Date Established September 1, 2023
Business Activities
  • Research, development, manufacturing, and sales of pharmaceuticals, medical devices, etc.
  • Acquisition, licensing, and management of intellectual property rights, etc.
  • Joint research and development projects with government agencies, research institutions, companies, etc.
  • Business related to the collection, processing, analysis, and provision of various information
  • Wholesale, brokerage, agency, and import/export business related to the preceding items
  • Marketing and consulting related to the preceding items
  • All businesses incidental or related to the preceding items
Location 22-3 Ichibancho, Chiyoda-ku, Tokyo
Teruyasu Nishino, President and CEO

President and CEO
Teruyasu Nishino

2002

Studied abroad in the US through Mayo Clinic Elective Clerkship

2003

Graduated from Juntendo University School of Medicine, obtained medical license

2011

Established Medical Corporation Yukokai, appointed Chairman

2015

Established Cardio Flow Design Inc.,
appointed Representative Director

2023

Established AntiCancer Technologies Inc.,
appointed Representative Director
Participates in multiple organizations including directorships in domestic companies, medical corporations, social welfare
corporations, and incorporated associations
Member of the Japanese Society of Plastic and Reconstructive Surgery, Member of the Japanese Orthopaedic Association

Keiichi Nakayama, CSO

Chief Scientific Officer (CSO)
Keiichi Nakayama

1986

Graduated from Tokyo Medical and Dental University, School of Medicine

1990

Completed graduate studies in immunology at Juntendo University Graduate School of Medicine (MD, PhD)

1995

Principal Researcher at Nippon Roche K.K.

1996

Professor at the Medical Institute of Bioregulation, Kyushu University

2021

Medal with Purple Ribbon

2023

Distinguished Professor at the Institute for Advanced Study, Tokyo Medical and Dental University

2024

Distinguished Professor at the Institute for Advanced Study, Tokyo Institute of Science and Technology

Tsugutoshi Kikuchi, COO

Chief Operating Officer (COO)
Tsugutoshi Kikuchi

1995

Graduated from the University of Chicago Booth School of Business (MBA Program)

1997–2002

Representative Director, Le Cordon Bleu Japan

2004–2007

Director, Apple Japan; Head of Apple Store

2007–2023

Regional Online Manager, Microsoft Japan

2023

Certified Sake Lecturer by the Food & Beverage Specialists Organization (FBO)

Ryuhei Okada, Assistant Professor, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University

Assistant Professor, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University
Ryuhei Okada

2009

Graduated from Tokyo Medical and Dental University, School of Medicine

2017

Completed graduate studies at Tokyo Medical and Dental University Graduate School of Medical and Dental Sciences (Clinical Anatomy)

2018

Engaged in basic research in the Molecular Imaging Branch, National Cancer Institute, USA

2021

Assistant Professor, Department of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University

History

September 1, 2023: AntiCancer Technologies Inc. established jointly by Distinguished Professor Keiichi Nakayama of Tokyo Medical and Dental University, Dr. Teruyasu Nishino (current President and CEO), Mr. Takafumi Horie, and others.
October 24, 2023: Filed basic patent for Pipeline 1.
February 21, 2024: Certified as a "Tokyo Medical and Dental University Startup" by Tokyo Medical and Dental University.
October 7, 2024: Selected as the 11th support recipient of the "1stRound" entrepreneurship support program by UTokyo Innovation Platform Co., Ltd. (UTokyo IPC).